AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $304.29 billion. The enterprise value is $360.23 billion.
| Market Cap | 304.29B |
| Enterprise Value | 360.23B |
Important Dates
The next confirmed earnings date is Thursday, July 25, 2024, before market open.
| Earnings Date | Jul 25, 2024 |
| Ex-Dividend Date | Jul 15, 2024 |
Share Statistics
AbbVie has 1.77 billion shares outstanding. The number of shares has decreased by -0.17% in one year.
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | -0.17% |
| Shares Change (QoQ) | -0.17% |
| Owned by Insiders (%) | 0.10% |
| Owned by Institutions (%) | 72.74% |
| Float | 1.76B |
Valuation Ratios
The trailing PE ratio is 51.13 and the forward PE ratio is 14.68. AbbVie's PEG ratio is 0.45.
| PE Ratio | 51.13 |
| Forward PE | 14.68 |
| PS Ratio | 5.59 |
| Forward PS | 5.33 |
| PB Ratio | 38.00 |
| P/FCF Ratio | 13.90 |
| PEG Ratio | 0.45 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.18, with an EV/FCF ratio of 16.46.
| EV / Earnings | 60.11 |
| EV / Sales | 6.62 |
| EV / EBITDA | 20.18 |
| EV / EBIT | 39.15 |
| EV / FCF | 16.46 |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 9.24.
| Current Ratio | 0.94 |
| Quick Ratio | 0.72 |
| Debt / Equity | 9.24 |
| Debt / EBITDA | 4.15 |
| Debt / FCF | 3.38 |
| Interest Coverage | 5.47 |
Financial Efficiency
Return on equity (ROE) is 55.30% and return on invested capital (ROIC) is 12.43%.
| Return on Equity (ROE) | 55.30% |
| Return on Assets (ROA) | 4.30% |
| Return on Capital (ROIC) | 12.43% |
| Revenue Per Employee | $1.09M |
| Profits Per Employee | $119,860 |
| Employee Count | 50,000 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 5.08 |
Taxes
In the past 12 months, AbbVie has paid $1.53 billion in taxes.
| Income Tax | 1.53B |
| Effective Tax Rate | 20.30% |
Stock Price Statistics
The stock price has increased by +25.16% in the last 52 weeks. The beta is 0.62, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +25.16% |
| 50-Day Moving Average | 165.99 |
| 200-Day Moving Average | 161.76 |
| Relative Strength Index (RSI) | 56.38 |
| Average Volume (20 Days) | 6,162,704 |
Short Selling Information
The latest short interest is 16.22 million, so 0.92% of the outstanding shares have been sold short.
| Short Interest | 16.22M |
| Short Previous Month | 16.49M |
| Short % of Shares Out | 0.92% |
| Short % of Float | 0.92% |
| Short Ratio (days to cover) | 2.53 |
Income Statement
In the last 12 months, AbbVie had revenue of $54.40 billion and earned $5.99 billion in profits. Earnings per share was $3.37.
| Revenue | 54.40B |
| Gross Profit | 33.88B |
| Operating Income | 12.79B |
| Pretax Income | 7.52B |
| Net Income | 5.99B |
| EBITDA | 17.85B |
| EBIT | 9.20B |
| Earnings Per Share (EPS) | $3.37 |
Balance Sheet
The company has $18.07 billion in cash and $74.00 billion in debt, giving a net cash position of -$55.93 billion or -$31.67 per share.
| Cash & Cash Equivalents | 18.07B |
| Total Debt | 74.00B |
| Net Cash | -55.93B |
| Net Cash Per Share | -$31.67 |
| Equity (Book Value) | 8.01B |
| Book Value Per Share | 4.53 |
| Working Capital | -2.65B |
Cash Flow
In the last 12 months, operating cash flow was $22.69 billion and capital expenditures -$795.00 million, giving a free cash flow of $21.89 billion.
| Operating Cash Flow | 22.69B |
| Capital Expenditures | -795.00M |
| Free Cash Flow | 21.89B |
| FCF Per Share | $12.38 |
Margins
Gross margin is 62.28%, with operating and profit margins of 23.50% and 11.02%.
| Gross Margin | 62.28% |
| Operating Margin | 23.50% |
| Pretax Margin | 13.82% |
| Profit Margin | 11.02% |
| EBITDA Margin | 32.81% |
| EBIT Margin | 16.91% |
| FCF Margin | 40.24% |
Dividends & Yields
This stock pays an annual dividend of $6.20, which amounts to a dividend yield of 3.60%.
| Dividend Per Share | $6.20 |
| Dividend Yield | 3.60% |
| Dividend Growth (YoY) | 4.79% |
| Years of Dividend Growth | 52 |
| Payout Ratio | 183.98% |
| Buyback Yield | 0.17% |
| Shareholder Yield | 3.77% |
| Earnings Yield | 1.97% |
| FCF Yield | 7.19% |
Analyst Forecast
The average price target for AbbVie is $185.00, which is 7.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $185.00 |
| Price Target Difference | 7.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 5.75% |
| EPS Growth Forecast (5Y) | 43.08% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AbbVie has an Altman Z-Score of 1.82 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.82 |
| Piotroski F-Score | 5 |